Pages that link to "Q27852275"
Jump to navigation
Jump to search
The following pages link to Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML (Q27852275):
Displaying 50 items.
- Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned (Q26738514) (← links)
- Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms (Q26778929) (← links)
- Chronic neutrophilic leukemia: a clinical perspective (Q26781167) (← links)
- JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications (Q26782539) (← links)
- Pathogenesis of myeloproliferative neoplasms (Q26799656) (← links)
- G-CSF and GM-CSF in Neutropenia (Q26800954) (← links)
- Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management (Q27009366) (← links)
- CIViC database (Q27612411) (← links)
- Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature (Q28083489) (← links)
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes (Q28392451) (← links)
- CSF3R Mutation (Q29920041) (← links)
- Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms (Q33417217) (← links)
- Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia (Q33417454) (← links)
- ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia (Q33421772) (← links)
- Activity of single-agent decitabine in atypical chronic myeloid leukemia (Q33425922) (← links)
- Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia (Q33591367) (← links)
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis (Q33697252) (← links)
- Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. (Q33794297) (← links)
- The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia (Q33796552) (← links)
- CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. (Q33909621) (← links)
- CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia (Q34355272) (← links)
- Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia (Q34700714) (← links)
- Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies (Q35132241) (← links)
- ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers (Q35542942) (← links)
- Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing (Q35610140) (← links)
- Therapeutically Targetable ALK Mutations in Leukemia (Q35676273) (← links)
- Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms (Q35727453) (← links)
- Diagnosis, complications and management of chronic neutrophilic leukaemia: A case report (Q35758855) (← links)
- Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report (Q35944494) (← links)
- Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database (Q36291255) (← links)
- Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development (Q36437137) (← links)
- Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis (Q36437173) (← links)
- Identification of AIM2 as a downstream target of JAK2V617F. (Q36513561) (← links)
- The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. (Q36535279) (← links)
- Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series (Q36693223) (← links)
- An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. (Q36708989) (← links)
- Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the γ-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case (Q36851425) (← links)
- Short telomere length and its correlation with gene mutations in myelodysplastic syndrome (Q37133403) (← links)
- The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment (Q37151676) (← links)
- BRCC3 mutations in myeloid neoplasms (Q37216363) (← links)
- The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition (Q37334721) (← links)
- Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes (Q37349392) (← links)
- The genetic basis of myelodysplasia and its clinical relevance (Q37390236) (← links)
- CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia (Q37431993) (← links)
- Functional genomics for personalized cancer therapy (Q37606889) (← links)
- What's different about atypical CML and chronic neutrophilic leukemia? (Q37606895) (← links)
- Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization (Q37608488) (← links)
- Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment (Q37615574) (← links)
- Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine (Q37676850) (← links)
- Myb expression is critical for myeloid leukemia development induced by Setbp1 activation (Q37699236) (← links)